The New England Journal of Medicine published results from a long-term study for the treatment of lupus nephritis.
Human Genome Sciences and GlaxoSmithKline Announce Publication Phase 3 Study Results for BENLYSTA®
February 08, 2011
ROCKVILLE, Maryland, and LONDON, UK – Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) announced publication of the BLISS-52 study of BENLYSTA® (belimumab) in autoantibody-positive patients with active systemic lupus erythematosus (SLE) in The Lancet.
Read more from HGSI
Read the LFA's research summary of the study
The U.S. Food and Drug Administration (FDA) approved the drug, BENLYSTA®, for the treatment of lupus, an autoimmune disease.